Resumen de New Anticoagulant Approved

Diane S. Aschenbrenner

• * Edoxaban (Savaysa) is a new oral anticoagulant used in the prevention of stroke and blood clots in patients with nonvalvular atrial fibrillation and in the treatment of deep vein thrombosis or pulmonary embolism. It inhibits the action of clotting factor Xa.

  * The most common adverse effects of edoxaban are anemia, bleeding, rash, and abnormal liver function. Like all anticoagulants, edoxaban carries a risk of bleeding, including major bleeding. Edoxaban shouldn't be used by those who have a creatinine clearance greater than 95 mL/min, indicating renal disease, because a long creatinine clearance increases the risk of ischemic stroke.